Clinical Research Details A Phase 3, multi-centre long-term extension study to assess the safety and efficacy of GSK3196165 in the treatment of rheumatoid arthritis. Study Description This is a long-term extension study of up to about 4 years for people with RA who may benefit from extended treatment with otilimab, after completing the treatment period from a previous otilimab clinical research study. Participants with rheumatoid arthritis who are aged =18 years at the time of signing informed consent, who have completed one of the qualifying GSK3196165 clinical studies, and who, in the opinion of the investigator, may benefit from treatment with GSK3196165. For participants on MTX: must be willing to continue treatment with oral folic acid (at least 5 mg/week) or equivalent while receiving MTX (mandatory co-medication for MTX treatment). Inclusion/Exclusion Criteria Not applicable Investigators Gurjit S. Kaeley, M.B.B.S. (M.D.) Medicine